{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=108",
    "query": {
      "intervention": "Placebo,",
      "page": 108
    },
    "page_size": 10
  },
  "pagination": {
    "page": 108,
    "page_size": 10,
    "total_count": 33216,
    "total_pages": 3322,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=109&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2C&page=107&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T22:58:18.695Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03710122",
      "title": "Vancomycin for Primary Sclerosing Cholangitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Elizabeth Carey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "18 Years to 76 Years"
      },
      "enrollment_count": 102,
      "start_date": "2020-01-23",
      "completion_date": "2025-03-20",
      "has_results": true,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 4,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03710122"
    },
    {
      "nct_id": "NCT00431951",
      "title": "Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ST-246",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SIGA Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2007-02",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00431951"
    },
    {
      "nct_id": "NCT01652729",
      "title": "Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide once weekly suspension",
          "type": "DRUG"
        },
        {
          "name": "Sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 365,
      "start_date": "2013-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2015-08-20",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01652729"
    },
    {
      "nct_id": "NCT00099203",
      "title": "A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Bone Neoplasm",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "ibandronate [Bondronat]",
          "type": "DRUG"
        },
        {
          "name": "zoledronic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2017-08-16",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Sedona, Arizona • Ocoee, Florida + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Ocoee",
          "state": "Florida"
        },
        {
          "city": "Macon",
          "state": "Georgia"
        },
        {
          "city": "Galesburg",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099203"
    },
    {
      "nct_id": "NCT03347188",
      "title": "A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Post-Traumatic Headache"
      ],
      "interventions": [
        {
          "name": "Fremanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 87,
      "start_date": "2017-12-18",
      "completion_date": "2020-06-03",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 33,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03347188"
    },
    {
      "nct_id": "NCT07667803",
      "title": "A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Weight Management"
      ],
      "interventions": [
        {
          "name": "Elecoglipron",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4500,
      "start_date": "2026-06-29",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667803"
    },
    {
      "nct_id": "NCT03586427",
      "title": "Zelquistinel in the Treatment of Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "AGN-241751",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Syndeio Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 251,
      "start_date": "2018-06-13",
      "completion_date": "2019-08-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 25,
      "location_summary": "Fayetteville, Arkansas • Cerritos, California • Encino, California + 20 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03586427"
    },
    {
      "nct_id": "NCT02397473",
      "title": "A Study Of Galcanezumab In Participants With Episodic Cluster Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Episodic Cluster Headache"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 109,
      "start_date": "2015-05-22",
      "completion_date": "2018-06-04",
      "has_results": true,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02397473"
    },
    {
      "nct_id": "NCT00360269",
      "title": "Atomoxetine Treatment for ADHD and Marijuana Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Marijuana Abuse",
        "Attention Deficit Disorder With Hyperactivity"
      ],
      "interventions": [
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Motivational enhancement therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2005-11",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-30",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360269"
    },
    {
      "nct_id": "NCT02534883",
      "title": "Cervical Ripening in Postmenopausal Women",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stenosis of Cervix"
      ],
      "interventions": [
        {
          "name": "Misoprostol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Louis University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "85 Years",
        "sex": "FEMALE",
        "summary": "45 Years to 85 Years · Female only"
      },
      "enrollment_count": 11,
      "start_date": "2015-08",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-11-20T22:58:18.695Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02534883"
    }
  ]
}